Johnson & Johnson increases its manufacturing in the United States as major pharmaceutical companies bring operations back to the country.

Johnson & Johnson plans to invest $55 billion over the next four years in U.S. manufacturing, research, and technology, marking a 25% increase from previous investments. This expansion includes the construction of a 500,000-square-foot biologics facility in North Carolina, which will create 500 permanent jobs and support 5,000 construction roles. The company cites rising demand for pharmaceuticals and the need to mitigate tariff impacts as key drivers for this move. J&J's annual contributions to the U.S. economy exceed $100 billion.